grant

Mechanisms of post-preeclampsia hypertension

Organization YALE UNIVERSITYLocation NEW HAVEN, UNITED STATESPosted 1 Feb 2024Deadline 31 Jan 2027
NIHUS FederalResearch GrantFY2026AdenoviridaeAdenovirusesAdipose tissueAdoptive TransferAffectAngIIAngiogenesis AntagonistsAngiogenesis BlockersAngiogenesis InhibitorsAngiogenetic AntagonistsAngiogenetic InhibitorsAngiogenic AntagonistsAngiogenic InhibitorsAngiostatic AgentsAngiotensin IIAnimal ModelAnimal Models and Related StudiesAnimalsAnti-Angiogenetic AgentsAnti-Angiogenic AgentsAnti-Angiogenic DrugsAnti-CD3 AntibodyAntiangiogenesis AgentsAntiangiogenic AgentsAntiangiogenic DrugsAntigen PresentationAntigen ReceptorsAntigensApoplexyAreaArteriesAutomobile DrivingB220BiologyBlood PressureBlood VesselsBrain Vascular AccidentC57BL/6 MouseCCL5CD3CD3 AntigensCD3 ComplexCD3 moleculeCD45CD62LCD8CD8BCD8B1CD8B1 geneCardiac DiseasesCardiac DisordersCardiac infarctionCardiovascularCardiovascular Body SystemCardiovascular DiseasesCardiovascular Organ SystemCardiovascular systemCell BodyCell LocomotionCell MigrationCell MovementCellsCells Placenta-TissueCellular MigrationCellular MotilityCerebral StrokeCerebrovascular ApoplexyCerebrovascular StrokeChemokine (C-C Motif) Ligand 5Chemotactic CytokinesClinicalD17S136EDataDietary SodiumDiseaseDisorderEPH GestosisESKDESRDEnd stage renal failureEnd-Stage Kidney DiseaseEnd-Stage Renal DiseaseEnvironmentEpidemiological dataEpidemiology dataEvaluationExhibitsExposure toFLK1Fatty TissueFemaleFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFutureGP180GestationGoalsHLHRCHeart DiseasesHeart VascularHomologous Chemotactic CytokinesHuM291HumanHypertensionHypoxiaHypoxicImmuneImmunesImmunologic TechnicsImmunologic TechniquesImmunological TechnicsImmunological TechniquesImmunologyIn VitroInfiltrationInflammationInflammatoryInjuryIntercrinesInvestigatorsKDR geneKidneyKidney Urinary SystemKnowledgeLAM-1 geneLECAM1LNHRLSELLY5LYAM-1LYAM1LYT3LinkLymphatic TissueLymphoidLymphoid TissueMGC17164Maternal HealthMaternal MortalityMaternal PhysiologyMeasuresMediatingMedical centerMentorsMiceMice MammalsMissionMoAb HuM291ModelingModern ManMonoclonal Antibody HuM291MurineMusMyocardial InfarctMyocardial InfarctionNational Institutes of HealthNeovascularization InhibitorsNephrologyNormal PlacentomaOKT3 antigenOrganOxygen DeficiencyPTPRCPTPRC genePathogenesisPhenotypePlacentaPlacenta Embryonic TissuePlacentomePopulationPostpartum HypertensionPostpartum PeriodPre-EclampsiaPreeclampsiaPregnancyPregnancy ComplicationsPregnancy ToxemiasProcessProductionProteinuria-Edema-Hypertension GestosisPublishingRANTESRenal CellResearch PersonnelResearchersResistanceRiskRoleSCYA5SELL geneSIS cytokinesSIS deltaSIS-deltaSISdSecondary HypertensionSelectin L GeneSmall Inducible Cytokine A5Sodium ChlorideStimulusStressStrokeStructureSyndromeT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell infiltrationT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT memory cellT-Cell DepletionT-Cell RANTES ProteinT-Cell Specific Protein p288T-CellsT-LymphocyteT-cell depletion therapyT-cell therapeuticsT-cell transfer therapyT-lymphocyte depletion therapyT200T3 AntigensT3 ComplexT3 moleculeTCP228TQ-1TechniquesTestingTrainingUnited States National Institutes of HealthUniversitiesVEGF ReceptorsVEGFRVEGFR-2VEGFR2VPF ReceptorVascular DiseasesVascular DisorderVascular Endothelial Cell Growth Factor ReceptorVascular Endothelial Growth Factor Receptor 2Vascular Hypertensive DiseaseVascular Hypertensive DisorderVascular Permeability Factor ReceptorVascular remodelingVasodilatationVasodilationVasorelaxationWomanadiposeadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyafter pregnancyantiangiogenicblood vessel disorderbrain attackcardiac infarctcardiovascular disordercardiovascular riskcardiovascular risk factorcell motilitycerebral vascular accidentcerebrovascular accidentchemoattractant cytokinechemokinecirculatory systemcomplications during pregnancycoronary attackcoronary infarctcoronary infarctioncytokinedietary Nadrivingepidemiologic datafemale treatmentflow cytophotometryheart attackheart disorderheart infarctheart infarctionhigh blood pressurehigh riskhyperpiesiahyperpiesishypertensivehypertensive diseasehypertensive disorderimmunogenimprovedinjuriesinsightkidney cellmalematernal deathmemory T lymphocytemigrationmodel of animalnoveloverexpressoverexpressionpost pregnancypost-partumpre-eclampticpregnancy toxemia/hypertensionpregnancy-related complicationspreventpreventingrenalresistantresponsesaltsocial rolestrokedstrokessystemic inflammationsystemic inflammatory responsetherapeutic T-cell platformthymus derived lymphocytetraining opportunitytreat femalestreat womentreatment among femalestreatment among womentreatment in femalestreatment in womenvascularvascular constrictionvascular dysfunctionvasculopathyvasoconstrictionwhite adipose tissuewomen's treatmentyellow adipose tissue
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Preeclampsia (PE) is a syndrome of new hypertension (HTN) with organ damage that occurs in
3-8% of pregnancies and is a leading cause of maternal mortality. Women who survive PE have

a substantially increased risk of future HTN, heart attack and stroke by unknown mechanisms.

These women have enhanced blood pressure and vasoconstriction responses to HTN stress that

persists months to years after PE. In male mice, T cells are necessary for hypertension and

effector memory T cells contribute to exacerbated responses to repetitive hypertensive stresses.

To explore mechanisms driving post-PE HTN, we modified two models of PE; one is induced by

overexpression of the anti-angiogenic soluble VEGF receptor 1 (sFlt1) during pregnancy and the

other is induced by hypoxia during pregnancy. I confirmed that both models cause increased sFlt1

and other features of PE seen in humans. Preliminary data in the sFlt1 model reveals that despite

post-partum sFlt1 levels and blood pressure normalizing: (1) post-partum microvascular

structure/function abnormalities persist; (2) post-partum HTN stimuli results in an exacerbated

blood pressure response, microvascular vasoconstriction and microvascular expression of the T-

cell chemokine, CCL5; and (3) kidney effector memory T cells are significantly increased after

HTN stimuli. Thus, I propose to test the hypothesis that experimental PE causes long-term T cell-

mediated changes in the microvasculature and kidney that increase sensitivity to post-partum

HTN stimuli. Aim 1 will examine if T cells are necessary for persistent vascular remodeling and

dysfunction after PE. T cell populations, migration and cytokine expression will be measured

during and after PE and in response to hypertensive stimuli. T cells will then be depleted and

blood pressure and vascular structure/function analyzed. Aim 2 will determine if adoptive transfer

of T cells exposed to PE is sufficient to induce the vascular and kidney changes associated with

post-PE HTN. Aim 3 will test the specific role of memory T cells in exacerbating the response to

hypertensive stimuli after PE. Completion of the aims will provide new insight into the mechanism

driving the substantial increase in HTN risk after PE, thereby supporting the NIH mission to

improve maternal health. The proposal will also allow me to gain new expertise in HTN diseases

of pregnancy and foundational immunology techniques. The mentoring team assembled on this

application, with expertise in cardiovascular immunology, nephrology, pregnancy and vascular

biology, the environment at Tufts Medical Center and Tufts University and the training plan

proposed will further strengthen my ability to become an independent investigator studying

mechanisms driving heart diseases in women.

Grant Number: 5R00HL161321-05
NIH Institute/Center: NIH

Principal Investigator: Lauren Biwer

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →